7:30 am Morning Refreshments & Check-In
8:25 am Chair’s Opening Remarks
Examining the Evolving Landscape of Obesity from New Targets to the Clinic to Inform & Update on the Future of Weight Loss Drug Development
8:30 am Surveying the Current Treatment Landscape, an Overview of the Eli Lilly Pipeline & the Role of GLP
Synopsis
- Analysing the current state of weight loss medications, including their efficacy, safety, and accessibility, to identify areas for improvement and inform future research
- Recognising the limitations of one-size-fits-all approaches, and the need for a shift towards a precision medicine framework for weight loss management
- Developing personalised treatment plans that consider an individual’s unique genetic makeup, metabolic profile, lifestyle factors, and social determinants of health
9:00 am MRI-based Body Composition Reimagined: Building a New Foundation for Treatment Differentiation Beyond Weight Loss
Synopsis
- FDA-cleared MRI-based body composition analysis provides a new standard for muscle and fat quantification enabling translation from population studies and clinical trials all the way into healthcare
- Studies on Personalized Fat and Muscle Z-score biomarkers show improved prediction of outcomes and that weight- and BMI-invariant treatment effects can be detected
- Understanding loss of muscle mass and shifts in fat distribution in the context of weight reduction and exploring the varying effects of liraglutide and tirzepatide in recent clinical trials
9:30 am Redefining Obesity & the Implications for Drug Development in the PostLancet Commission Era to Improve Patient Treatment for More Effective Weight Management
Synopsis
- Redefining obesity beyond BMI, emphasizing health outcomes and moving towards a more personalized approach based on the Lancet Commission on Obesity’s recommendations
- Prioritizing targets that address the underlying causes of clinical obesity and its complications, developing personalized therapies, and emphasizing clinical endpoints that reflect improved health outcomes
- Understanding the challenges of implementing this new approach, such as developing accurate diagnostic tools and addressing the complexities of personalized medicine as well as highlighting the significant opportunities for innovation and improved patient outcomes Charlie Harris Associate Vice President Eli Lilly
10:00 am Morning Break & Speed Networking
Synopsis
Put a face to a name – this session is the perfect opportunity to get face-to-face time with key opinion leaders, leading companies, and innovative researchers in obesity drug development. Establish meaningful connections to build upon for the rest of the conference and gain individual insight beyond the papers and press releases into the pioneering research and therapeutic development
Evolving the Obesity Landscape of GLP-1s with Combination Therapies to Improve Efficacy, Personalize Patient Treatment & Manage Side Effects
11:00 am Why Physiologically-Regulated GLP-1 May Improve the Efficacy and Tolerability of Weight Loss Therapeutics
Synopsis
- Mimicking the physiologic secretion profile of GLP-1 to provide receptor agonism when it is needed, for improved efficacy and tolerability
- Targeting individual patient needs by developing a platform for several multi-agonist therapies
- Reducing treatment burden with a one-time, life-long therapy
11:30 am Underneath the Lost Kilos: Imaging in Obesity and Metabolic Disease Drug Development
Synopsis
- Imaging methodologies (e.g. DXA, MRI) provide information about different aspects of body composition meeting different needs in clinical trials
- Body composition assessment of muscle and adipose tissue can be combined with measures of other end-organ effects for a deeper understanding of treatment responses
- MRI-based methods can also provide detailed insights into muscle composition including inter- and intramuscular fat, glycogen, sodium and functional readouts
12:00 pm Optimizing Patient Adherence in Clinical Trials: Behavioral Evaluation, Risk Prediction, and Personalized Digital Interventions
Synopsis
- Adherence and retention are critical for clinical trial success. Every participant who discontinues study drug or drops out of a study reduces its statistical power and its credibility
- SPUR is a unique adherence solution that offers a validated individual behavioral diagnosis and intervention plan for each participant
- SPUR stands for the 4 key determinants of the beliefs, attitudes and behaviors of patients – Social, Psychological, Usage, and Rational – unique for every patient or research participant. A simple, validated, electronic questionnaire feeds into the SPUR analysis, which provides
- SPUR has been used to improve medication adherence in >100,000 patients globally, and Clinical ink is using SPUR to optimize adherence and retention in clinical trials.
12:10 pm Lunch & Networking
1:10 pm Mechanistic Insights Into Survodutide, a Dual Glucagon/GLP-1 Receptor Agonist, for Obesity Treatment
Synopsis
- Exploring the potential of dual and triple receptor agonists targeting multiple pathways involved in energy regulation, such as GLP-1, GIP, and glucagon receptors, to achieve weight loss with improved tolerability profiles
- Evaluating their clinical and metabolic benefits, and their potential to address gastrointestinal side effects while maintaining potent weight loss efficacy
- Understanding receptor interactions and signalling pathways used by these multireceptor agonists to optimise their therapeutic potential and identify patient populations that may benefit from these innovative approaches
Investigating Novel Therapeutic Targets Beyond GLP-1 to Explore the Future of More Efficacious Obesity Treatment
1:40 pm Adding a Gut-Liver Targeted Metabolic Modulator Using Novel Inflammatory Pathways for Increased Metabolic Benefits
Synopsis
- Targeting novel inflammatory pathways within the gut-liver axis presents a promising strategy for developing innovative metabolic modulators
- Leveraging these modulators in combination with existing therapies, such as GLP-1 receptor agonists, to offer enhanced metabolic benefits, including improved weight loss, glycemic control, and reduced hepatic steatosis
- Providing a treatment with better ease of patient use for better weight maintenance
2:10 pm Drug Efficacy Studies in Diet-Induced Obese Rodent Models: Can We Predict the Metabolic Benefits of Weight-Lowering Therapies?
Synopsis
- What can we get from the diet-induced obese mouse model?
- What about the diet-induced obese rat model?
- The free choice diet-induced obese hamster, a new model to demonstrate therapies potential for patients: Weight loss/regain, food preference, alcohol intake, dyslipidemia, MASH and HFpEF
Maintaining Muscle Mass & Strategies to Prevent Sarcopenia in Obesity Treatment
2:40 pm Muscle-Targeted Therapeutics That Can Be Combined with Obesity Drugs to Improve the Quality of Weight Management
Synopsis
- Addressing the concern of muscle loss, as a side effect of GLP-1 medications, through the development of muscle preservation and stimulation approaches
- Exploring the synergistic potential of combining these muscle stimulants with existing obesity therapies to improve weight loss outcomes
- Optimizing the development of safe and effective muscle stimulants by focusing on specific targets and innovative delivery mechanisms
3:10 pm Afternoon Networking Break & Poster Session
Synopsis
Connect with peers in a relaxed atmosphere and continue to forge new and existing relationships while exploring the latest in obesity and weight loss research and advancements. To submit a poster, please contact info@hansonwade.com
4:00 pm GLP-1s in the Real World: What EHR Data Reveals About Use, Outcomes, & Access
Synopsis
- Who’s using GLP-1s – and how that’s changing over time: Explore real-world trends in prescribing across demographics
- What happens after initiation: Dive into patterns of discontinuation, reinitiation – and the factors driving those choices
- How does effectiveness compare: See how tirzepatide and semaglutide stack up on real-world weight loss outcome
4:30 pm Targeting the TGF-Beta Superfamily With Extended Half-Life Antibodies to Enable Improved Quality of Weight Loss
Synopsis
- Long half life antibodies can reduce dose volume and frequency without sacrificing efficacy
- Inhibition of myostatin can counter lean mass loss and potentially enable improved patient experience and outcomes
- Additional targets and combinations of targets within the TGF-beta superfamily can enable further improvements in weight loss quality